Karyopharm Therapeutics Inc. (KPTI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Karyopharm Therapeutics reported revenue of $146.1M, up 0.6% from $145.2M the year before. Net income was -$196.0M (a -134.2% net margin), or -$17.93 per diluted share. Gross margin was 95.9% and operating margin was -62.1%. Operating activities generated -$75.4M of cash. At fiscal year end, Karyopharm Therapeutics held $108.4M in total assets against $401.3M in total liabilities, including $60.5M of cash and equivalents.
Open the full interactive Karyopharm Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Karyopharm Therapeutics Key Stats
| Share Price | $0.43 |
|---|---|
| Market Cap | $12.4M |
| Revenue YoY Growth | +0.6% |
| 52-Week Range | $0.43 – $10.67 |
| Shares Outstanding | 28.9 million (basic, 2026 Q2) |
Karyopharm Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Cost of Goods Sold | — | — | $5.2M | $4.9M | $6.0M | $5.9M |
| Gross Profit | — | — | $151.9M | $141.1M | $139.2M | $140.1M |
| Operating Income | -$171.8M | -$98.3M | -$142.2M | -$129.5M | -$119.4M | -$90.7M |
| Pre-Tax Income | -$196.0M | -$123.8M | -$164.9M | -$142.8M | -$76.4M | -$196.0M |
| Income Tax | $309,000 | $268,000 | $369,000 | $323,000 | $57,000 | $43,000 |
| Net Income | -$196.3M | -$124.1M | -$165.3M | -$143.1M | -$76.4M | -$196.0M |
| Diluted EPS | -$40.80 | -$24.75 | -$30.30 | -$18.75 | -$13.95 | -$17.93 |
Karyopharm Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $44.0M | $34.1M | $35.1M | $33.4M |
| Net Income | -$33.1M | -$102.2M | -$22.4M | -$67.0M |
| Diluted EPS | -$3.82 | -$9.35 | -$1.24 | -$2.32 |
Karyopharm Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.9M | $190.5M | $135.2M | $52.2M | $62.5M | $60.5M |
| Current Assets | $276.5M | $275.6M | $350.2M | $233.9M | $156.5M | $103.1M |
| Total Assets | $313.1M | $305.3M | $358.2M | $240.4M | $164.4M | $108.4M |
| Current Liabilities | $60.2M | $73.7M | $65.9M | $69.5M | $92.3M | $92.1M |
| Total Long-Term Debt | $117.9M | $169.3M | $170.1M | $170.9M | $94.6M | $115.8M |
| Total Liabilities | $262.5M | $385.0M | $374.8M | $376.6M | $350.4M | $401.3M |
| Shareholders' Equity | $50.5M | -$79.7M | -$16.7M | -$136.2M | -$186.0M | -$292.9M |
Karyopharm Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$160.2M | -$107.1M | -$149.6M | -$92.7M | -$127.5M | -$75.4M |
| Cash From Investing | -$53.7M | $141.8M | -$104.3M | $7.9M | $95.5M | $43.4M |
| Cash From Financing | $172.1M | $73.6M | $193.7M | $1.1M | $41.6M | $30.0M |
| Free Cash Flow | -$160.4M | -$107.3M | -$149.7M | -$92.7M | -$127.6M | -$75.4M |
Figures from Karyopharm Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Karyopharm Therapeutics financials page for every line item.
Karyopharm Therapeutics Company Profile
| Ticker | KPTI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newton, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001503802 |
Frequently Asked Questions
What was Karyopharm Therapeutics' revenue in fiscal 2025?
Karyopharm Therapeutics (KPTI) reported revenue of $146.1M for fiscal 2025.
What is Karyopharm Therapeutics' annual revenue history?
Karyopharm Therapeutics' annual revenue by fiscal year: 2020: $108.1M; 2021: $209.8M; 2022: $157.1M; 2023: $146.0M; 2024: $145.2M; 2025: $146.1M.
What was Karyopharm Therapeutics' net income in fiscal 2025?
Karyopharm Therapeutics reported net income of -$196.0M for fiscal 2025.
What was Karyopharm Therapeutics' earnings per share (EPS) in fiscal 2025?
Karyopharm Therapeutics' diluted EPS was -$17.93 for fiscal 2025 (adjusted for any later stock splits).
What was Karyopharm Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Karyopharm Therapeutics reported revenue of $33.4M.
How much debt does Karyopharm Therapeutics have?
Karyopharm Therapeutics reported $115.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Karyopharm Therapeutics are outstanding?
Karyopharm Therapeutics reported a weighted average of 28.9 million basic shares outstanding in 2026 Q2.
What is Karyopharm Therapeutics' market cap?
Based on its latest closing price, Karyopharm Therapeutics (KPTI) has a market capitalization of about $12.4M.
When does Karyopharm Therapeutics' fiscal year end?
Karyopharm Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Karyopharm Therapeutics headquartered?
Karyopharm Therapeutics lists its business address in Newton, Massachusetts in its SEC filings.